| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2021: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2020: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
|
|---|
| Outline of Final Research Achievements |
To prevent cerebral vasospasm and symptom exacerbation after subarachnoid hemorrhage (SAH), the researchers, in collaboration with Professor Ann Marie Schmidt of New York University, USA, administered compound 11, a novel RAGE inhibitor, to mice and investigated its effect on the pathological state after SAH. As a result, they confirmed that the compound markedly improved neurological symptoms and cerebral vasospasm. Furthermore, the researchers employed cell-specific RAGE-conditional knockout (cKO) mice and found that neutrophil-derived RAGE plays an important role in the pathogenesis of post-SAH.
|
